Read this company snapshot
Daily valuation snapshot
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $79.78
- Market capitalization (USD)
- $6,224,755,757.14
- Price / earnings (TTM)
- 77.17
- Price / book
- 9.52
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research KNSA in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research KNSA in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing KNSA with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $79.78 |
| Market capitalization (USD) | $6,224,755,757.14 |
| Price / earnings (TTM) | 77.17 |
| Price / book | 9.52 |
No matching rows. Clear the filter to see all records.
Read KNSA's valuation metrics
Company size
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's recorded market capitalization is $6,224,755,757.14. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
KNSA's recorded P/E is 77.17: about $77.17 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
KNSA's recorded price-to-book ratio is 9.52. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares with Aurora
Use the snapshot above to ask a specific question about KNSA. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow KNSA's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.